BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hennika T, Hu G, Olaciregui NG, Barton KL, Ehteda A, Chitranjan A, Chang C, Gifford AJ, Tsoli M, Ziegler DS, Carcaboso AM, Becher OJ. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models. PLoS One 2017;12:e0169485. [PMID: 28052119 DOI: 10.1371/journal.pone.0169485] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 16.4] [Reference Citation Analysis]
Number Citing Articles
1 Liu G, Qiu Y, Zhang P, Chen Z, Chen S, Huang W, Wang B, Yu X, Guo D. Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies. Pharmaceutics 2022;14:1762. [DOI: 10.3390/pharmaceutics14091762] [Reference Citation Analysis]
2 Power EA, Rechberger JS, Gupta S, Schwartz JD, Daniels DJ, Khatua S. Drug delivery across the blood-brain barrier for the treatment of pediatric brain tumors - An update. Adv Drug Deliv Rev 2022;185:114303. [PMID: 35460714 DOI: 10.1016/j.addr.2022.114303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Markouli M, Strepkos D, Papavassiliou KA, Papavassiliou AG, Piperi C. Crosstalk of Epigenetic and Metabolic Signaling Underpinning Glioblastoma Pathogenesis. Cancers 2022;14:2655. [DOI: 10.3390/cancers14112655] [Reference Citation Analysis]
4 Lewis NA, Klein RH, Kelly C, Yee J, Knoepfler PS. Histone H3.3 K27M chromatin functions implicate a network of neurodevelopmental factors including ASCL1 and NEUROD1 in DIPG. Epigenetics Chromatin 2022;15:18. [PMID: 35590427 DOI: 10.1186/s13072-022-00447-6] [Reference Citation Analysis]
5 Zhou Q, Xu Y, Zhou Y, Wang J. Promising Chemotherapy for Malignant Pediatric Brain Tumor in Recent Biological Insights. Molecules 2022;27:2685. [PMID: 35566032 DOI: 10.3390/molecules27092685] [Reference Citation Analysis]
6 Pienkowski T, Kowalczyk T, Garcia-Romero N, Ayuso-Sacido A, Ciborowski M. Proteomics and metabolomics approach in adult and pediatric glioma diagnostics. Biochim Biophys Acta Rev Cancer 2022;:188721. [PMID: 35304294 DOI: 10.1016/j.bbcan.2022.188721] [Reference Citation Analysis]
7 Badodi S, Marino S. Epigenetic mechanisms in paediatric brain tumours: regulators lose control. Biochem Soc Trans 2022;50:167-85. [PMID: 35076654 DOI: 10.1042/BST20201227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Hayden E, Holliday H, Lehmann R, Khan A, Tsoli M, Rayner BS, Ziegler DS. Therapeutic Targets in Diffuse Midline Gliomas-An Emerging Landscape. Cancers (Basel) 2021;13:6251. [PMID: 34944870 DOI: 10.3390/cancers13246251] [Reference Citation Analysis]
9 Galanis E, Wen PY, de Groot JF, Weller M. Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma. Hematol Oncol Clin North Am 2022;36:113-32. [PMID: 34756799 DOI: 10.1016/j.hoc.2021.08.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Rakotomalala A, Bailleul Q, Savary C, Arcicasa M, Hamadou M, Huchedé P, Hochart A, Restouin A, Castellano R, Collette Y, Dieny E, Vincent A, Angrand PO, Le Bourhis X, Leblond P, Furlan A, Castets M, Pasquier E, Meignan S. H3.3K27M Mutation Controls Cell Growth and Resistance to Therapies in Pediatric Glioma Cell Lines. Cancers (Basel) 2021;13:5551. [PMID: 34771714 DOI: 10.3390/cancers13215551] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Argersinger DP, Rivas SR, Shah AH, Jackson S, Heiss JD. New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma. Cancers (Basel) 2021;13:5280. [PMID: 34771443 DOI: 10.3390/cancers13215280] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Leszczynska KB, Jayaprakash C, Kaminska B, Mieczkowski J. Emerging Advances in Combinatorial Treatments of Epigenetically Altered Pediatric High-Grade H3K27M Gliomas. Front Genet 2021;12:742561. [PMID: 34646308 DOI: 10.3389/fgene.2021.742561] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Chong WC, Jayasekara WSN, Vaghjiani VG, Parackal S, Sun C, Popovski D, Algar EM, Firestein R, Wood PJ, Khan S, Huang A, Ashley DM, Downie P, Cain JE. Atypical Teratoid Rhabdoid Tumours Are Susceptible to Panobinostat-Mediated Differentiation Therapy. Cancers (Basel) 2021;13:5145. [PMID: 34680294 DOI: 10.3390/cancers13205145] [Reference Citation Analysis]
14 M Kholosy W, Derieppe M, van den Ham F, Ober K, Su Y, Custers L, Schild L, M J van Zogchel L, M Wellens L, R Ariese H, Szanto CL, Wienke J, Dierselhuis MP, van Vuurden D, Dolman EM, Molenaar JJ. Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies. J Pers Med 2021;11:869. [PMID: 34575646 DOI: 10.3390/jpm11090869] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Sears TK, Horbinski CM, Woolard KD. IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat. J Neurooncol 2021;154:159-70. [PMID: 34424450 DOI: 10.1007/s11060-021-03829-0] [Reference Citation Analysis]
16 Harttrampf AC, da Costa MEM, Renoult A, Daudigeos-Dubus E, Geoerger B. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation. BMC Cancer 2021;21:833. [PMID: 34281526 DOI: 10.1186/s12885-021-08579-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Price G, Bouras A, Hambardzumyan D, Hadjipanayis CG. Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma. EBioMedicine 2021;69:103453. [PMID: 34157482 DOI: 10.1016/j.ebiom.2021.103453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
18 Homan MJ, Franson A, Ravi K, Roberts H, Pai MP, Liu C, He M, Matvekas A, Koschmann C, Marini BL. Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model. Cancer Chemother Pharmacol 2021;88:555-62. [PMID: 34115161 DOI: 10.1007/s00280-021-04313-2] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
19 Xiao L, Somers K, Murray J, Pandher R, Karsa M, Ronca E, Bongers A, Terry R, Ehteda A, Gamble LD, Issaeva N, Leonova KI, O'Connor A, Mayoh C, Venkat P, Quek H, Brand J, Kusuma FK, Pettitt JA, Mosmann E, Kearns A, Eden G, Alfred S, Allan S, Zhai L, Kamili A, Gifford AJ, Carter DR, Henderson MJ, Fletcher JI, Marshall G, Johnstone RW, Cesare AJ, Ziegler DS, Gudkov AV, Gurova KV, Norris MD, Haber M. Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. Clin Cancer Res 2021;27:4338-52. [PMID: 33994371 DOI: 10.1158/1078-0432.CCR-20-2357] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
20 Miklja Z, Pasternak A, Stallard S, Nicolaides T, Kline-Nunnally C, Cole B, Beroukhim R, Bandopadhayay P, Chi S, Ramkissoon SH, Mullan B, Bruzek AK, Gauthier A, Garcia T, Atchison C, Marini B, Fouladi M, Parsons DW, Leary S, Mueller S, Ligon KL, Koschmann C. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro Oncol 2019;21:968-80. [PMID: 30805642 DOI: 10.1093/neuonc/noz022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 25] [Article Influence: 14.0] [Reference Citation Analysis]
21 Skwarska A, Calder EDD, Sneddon D, Bolland H, Odyniec ML, Mistry IN, Martin J, Folkes LK, Conway SJ, Hammond EM. Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor. Cell Chem Biol 2021:S2451-9456(21)00159-8. [PMID: 33910023 DOI: 10.1016/j.chembiol.2021.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Ehteda A, Simon S, Franshaw L, Giorgi FM, Liu J, Joshi S, Rouaen JRC, Pang CNI, Pandher R, Mayoh C, Tang Y, Khan A, Ung C, Tolhurst O, Kankean A, Hayden E, Lehmann R, Shen S, Gopalakrishnan A, Trebilcock P, Gurova K, Gudkov AV, Norris MD, Haber M, Vittorio O, Tsoli M, Ziegler DS. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Rep 2021;35:108994. [PMID: 33852836 DOI: 10.1016/j.celrep.2021.108994] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
23 Patel JP, Spiller SE, Barker ED. Drug penetration in pediatric brain tumors: Challenges and opportunities. Pediatr Blood Cancer 2021;68:e28983. [PMID: 33719183 DOI: 10.1002/pbc.28983] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Ung C, Tsoli M, Liu J, Cassano D, Pocoví-Martínez S, Upton DH, Ehteda A, Mansfeld FM, Failes TW, Farfalla A, Katsinas C, Kavallaris M, Arndt GM, Vittorio O, Cirillo G, Voliani V, Ziegler DS. Doxorubicin-Loaded Gold Nanoarchitectures as a Therapeutic Strategy against Diffuse Intrinsic Pontine Glioma. Cancers (Basel) 2021;13:1278. [PMID: 33805713 DOI: 10.3390/cancers13061278] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
25 Chen Z, Peng P, Zhang X, Mania-Farnell B, Xi G, Wan F. Advanced Pediatric Diffuse Pontine Glioma Murine Models Pave the Way towards Precision Medicine. Cancers (Basel) 2021;13:1114. [PMID: 33807733 DOI: 10.3390/cancers13051114] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Bressan RB, Southgate B, Ferguson KM, Blin C, Grant V, Alfazema N, Wills JC, Marques-Torrejon MA, Morrison GM, Ashmore J, Robertson F, Williams CAC, Bradley L, von Kriegsheim A, Anderson RA, Tomlinson SR, Pollard SM. Regional identity of human neural stem cells determines oncogenic responses to histone H3.3 mutants. Cell Stem Cell 2021;28:877-893.e9. [PMID: 33631116 DOI: 10.1016/j.stem.2021.01.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
27 Al Shoyaib A, Alamri FF, Syeara N, Jayaraman S, Karamyan ST, Arumugam TV, Karamyan VT. The Effect of Histone Deacetylase Inhibitors Panobinostat or Entinostat on Motor Recovery in Mice After Ischemic Stroke. Neuromolecular Med 2021. [PMID: 33590407 DOI: 10.1007/s12017-021-08647-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
28 Khan A, Gamble LD, Upton DH, Ung C, Yu DMT, Ehteda A, Pandher R, Mayoh C, Hébert S, Jabado N, Kleinman CL, Burns MR, Norris MD, Haber M, Tsoli M, Ziegler DS. Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas. Nat Commun 2021;12:971. [PMID: 33579942 DOI: 10.1038/s41467-021-20896-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
29 Mendez FM, Núñez FJ, Garcia-Fabiani MB, Haase S, Carney S, Gauss JC, Becher OJ, Lowenstein PR, Castro MG. Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease. Neuro Oncol 2020;22:195-206. [PMID: 32078691 DOI: 10.1093/neuonc/noz218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
30 Tan JY, Wijesinghe IVS, Alfarizal Kamarudin MN, Parhar I. Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid Biopsies. Cancers (Basel) 2021;13:607. [PMID: 33557011 DOI: 10.3390/cancers13040607] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
31 Chatwin HV, Cruz Cruz J, Green AL. Pediatric high-grade glioma: moving toward subtype-specific multimodal therapy. FEBS J 2021;288:6127-41. [PMID: 33523591 DOI: 10.1111/febs.15739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
32 Wummer B, Woodworth D, Flores C. Brain stem gliomas and current landscape. J Neurooncol 2021;151:21-8. [PMID: 33398531 DOI: 10.1007/s11060-020-03655-w] [Reference Citation Analysis]
33 Alencastro Veiga Cruzeiro G, Rota C, Hack OA, Segal R, Filbin MG. Understanding the epigenetic landscape and cellular architecture of childhood brain tumors. Neurochem Int 2021;144:104940. [PMID: 33333210 DOI: 10.1016/j.neuint.2020.104940] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Mueller T, Stucklin ASG, Postlmayr A, Metzger S, Gerber N, Kline C, Grotzer M, Nazarian J, Mueller S. Advances in Targeted Therapies for Pediatric Brain Tumors. Curr Treat Options Neurol 2020;22. [DOI: 10.1007/s11940-020-00651-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Thomas L, Smith N, Saunders D, Zalles M, Gulej R, Lerner M, Fung KM, Carcaboso AM, Towner RA. OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma. J Transl Med 2020;18:424. [PMID: 33168005 DOI: 10.1186/s12967-020-02593-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
36 Zugbi S, Ganiewich D, Bhattacharyya A, Aschero R, Ottaviani D, Sampor C, Cafferata EG, Mena M, Sgroi M, Winter U, Lamas G, Suñol M, Daroqui M, Baialardo E, Salas B, Das A, Fandiño A, Francis JH, Lubieniecki F, Lavarino C, Garippa R, Podhajcer OL, Abramson DH, Radvanyi F, Chantada G, Llera AS, Schaiquevich P. Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma. Cancers (Basel) 2020;12:E2714. [PMID: 32971811 DOI: 10.3390/cancers12092714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
37 Tosi U, Kommidi H, Adeuyan O, Guo H, Maachani UB, Chen N, Su T, Zhang G, Pisapia DJ, Dahmane N, Ting R, Souweidane MM. PET, image-guided HDAC inhibition of pediatric diffuse midline glioma improves survival in murine models. Sci Adv 2020;6:eabb4105. [PMID: 32832670 DOI: 10.1126/sciadv.abb4105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
38 Perla A, Fratini L, Cardoso PS, Nör C, Brunetto AT, Brunetto AL, de Farias CB, Jaeger M, Roesler R. Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential. Front Cell Dev Biol 2020;8:546. [PMID: 32754588 DOI: 10.3389/fcell.2020.00546] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
39 Duke ES, Packer RJ. Update on Pediatric Brain Tumors: the Molecular Era and Neuro-immunologic Beginnings. Curr Neurol Neurosci Rep. 2020;20:30. [PMID: 32564169 DOI: 10.1007/s11910-020-01050-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Packer RJ, Kilburn L. Molecular-Targeted Therapy for Childhood Brain Tumors: A Moving Target. J Child Neurol 2020;35:791-8. [PMID: 32552173 DOI: 10.1177/0883073820931635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
41 Felker J, Broniscer A. Improving long-term survival in diffuse intrinsic pontine glioma. Expert Rev Neurother 2020;20:647-58. [PMID: 32543245 DOI: 10.1080/14737175.2020.1775584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Deligne C, Hachani J, Duban-Deweer S, Meignan S, Leblond P, Carcaboso AM, Sano Y, Shimizu F, Kanda T, Gosselet F, Dehouck MP, Mysiorek C. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance. Fluids Barriers CNS 2020;17:37. [PMID: 32487241 DOI: 10.1186/s12987-020-00198-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
43 Milazzo G, Mercatelli D, Di Muzio G, Triboli L, De Rosa P, Perini G, Giorgi FM. Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability. Genes (Basel) 2020;11:E556. [PMID: 32429325 DOI: 10.3390/genes11050556] [Cited by in Crossref: 39] [Cited by in F6Publishing: 73] [Article Influence: 19.5] [Reference Citation Analysis]
44 Chaves C, Declèves X, Taghi M, Menet MC, Lacombe J, Varlet P, Olaciregui NG, Carcaboso AM, Cisternino S. Characterization of the Blood-Brain Barrier Integrity and the Brain Transport of SN-38 in an Orthotopic Xenograft Rat Model of Diffuse Intrinsic Pontine Glioma. Pharmaceutics 2020;12:E399. [PMID: 32349240 DOI: 10.3390/pharmaceutics12050399] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
45 Aziz-Bose R, Monje M. Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets. Curr Opin Oncol 2019;31:522-30. [PMID: 31464759 DOI: 10.1097/CCO.0000000000000577] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
46 Boulet MHC, Marsh LK, Howarth A, Woolman A, Farrer NJ. Oxaliplatin and [Pt(R,R-DACH)(panobinostat-2H)] show nanomolar cytotoxicity towards diffuse intrinsic pontine glioma (DIPG). Dalton Trans 2020;49:5703-10. [PMID: 32297619 DOI: 10.1039/c9dt04862f] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Capdevielle C, Desplat A, Charpentier J, Sagliocco F, Thiebaud P, Thézé N, Fédou S, Hooks KB, Silvestri R, Guyonnet-Duperat V, Petrel M, Raymond AA, Dupuy JW, Grosset CF, Hagedorn M. HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53. Neuro Oncol 2020;22:550-62. [PMID: 31711240 DOI: 10.1093/neuonc/noz215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Hanz SZ, Adeuyan O, Lieberman G, Hennika T. Clinical trials using molecular stratification of pediatric brain tumors. Transl Pediatr 2020;9:144-56. [PMID: 32477915 DOI: 10.21037/tp.2020.03.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Rashed WM, Maher E, Adel M, Saber O, Zaghloul MS. Pediatric diffuse intrinsic pontine glioma: where do we stand? Cancer Metastasis Rev 2019;38:759-70. [PMID: 31802357 DOI: 10.1007/s10555-019-09824-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
50 Kluiver TA, Alieva M, van Vuurden DG, Wehrens EJ, Rios AC. Invaders Exposed: Understanding and Targeting Tumor Cell Invasion in Diffuse Intrinsic Pontine Glioma. Front Oncol 2020;10:92. [PMID: 32117746 DOI: 10.3389/fonc.2020.00092] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
51 Wierzbicki K, Ravi K, Franson A, Bruzek A, Cantor E, Harris M, Homan MJ, Marini BL, Kawakibi AR, Ravindran R, Teodoro R, Yadav VN, Koschmann C. Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma. Curr Oncol Rep 2020;22:19. [PMID: 32030483 DOI: 10.1007/s11912-020-0877-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
52 Theeler BJ, Dalal Y, Monje M, Shilatifard A, Suvà ML, Aboud O, Camphausen K, Cordova C, Finch E, Heiss JD, Packer RJ, Romo CG, Aldape K, Penas-Prado M, Armstrong T, Gilbert MR. NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop Proceedings. Neurooncol Adv 2020;2:vdaa007. [PMID: 32642676 DOI: 10.1093/noajnl/vdaa007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Kasper LH, Baker SJ. Invited Review: Emerging functions of histone H3 mutations in paediatric diffuse high-grade gliomas. Neuropathol Appl Neurobiol 2020;46:73-85. [PMID: 31859390 DOI: 10.1111/nan.12591] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
54 Rodgers LT, Lester McCully CM, Odabas A, Cruz R, Peer CJ, Figg WD, Warren KE. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma. Cancer Chemother Pharmacol 2020;85:827-30. [PMID: 31894347 DOI: 10.1007/s00280-019-04021-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
55 Blandin AF, Durand A, Litzler M, Tripp A, Guérin É, Ruhland E, Obrecht A, Keime C, Fuchs Q, Reita D, Lhermitte B, Coca A, Jones C, Rebel IL, Villa P, Namer IJ, Dontenwill M, Guenot D, Entz-Werle N. Hypoxic Environment and Paired Hierarchical 3D and 2D Models of Pediatric H3.3-Mutated Gliomas Recreate the Patient Tumor Complexity. Cancers (Basel) 2019;11:E1875. [PMID: 31779235 DOI: 10.3390/cancers11121875] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
56 Bornhorst M, Hwang EI. Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors. Pediatr Drugs 2020;22:45-54. [DOI: 10.1007/s40272-019-00369-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
57 Kangussu-Marcolino MM, Ehrenkaufer GM, Chen E, Debnath A, Singh U. Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia. Int J Parasitol Drugs Drug Resist 2019;11:80-94. [PMID: 31707263 DOI: 10.1016/j.ijpddr.2019.10.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
58 Anastas JN, Zee BM, Kalin JH, Kim M, Guo R, Alexandrescu S, Blanco MA, Giera S, Gillespie SM, Das J, Wu M, Nocco S, Bonal DM, Nguyen QD, Suva ML, Bernstein BE, Alani R, Golub TR, Cole PA, Filbin MG, Shi Y. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. Cancer Cell 2019;36:528-544.e10. [PMID: 31631026 DOI: 10.1016/j.ccell.2019.09.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 72] [Article Influence: 17.0] [Reference Citation Analysis]
59 Duchatel RJ, Jackson ER, Alvaro F, Nixon B, Hondermarck H, Dun MD. Signal Transduction in Diffuse Intrinsic Pontine Glioma. Proteomics 2019;19:1800479. [DOI: 10.1002/pmic.201800479] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
60 Meel MH, Kaspers GJL, Hulleman E. Preclinical therapeutic targets in diffuse midline glioma. Drug Resist Updat 2019;44:15-25. [PMID: 31202081 DOI: 10.1016/j.drup.2019.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
61 Chang R, Tosi U, Voronina J, Adeuyan O, Wu LY, Schweitzer ME, Pisapia DJ, Becher OJ, Souweidane MM, Maachani UB. Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy. Neurooncol Adv 2019;1:vdz004. [PMID: 32642647 DOI: 10.1093/noajnl/vdz004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
62 Gallitto M, Lazarev S, Wasserman I, Stafford JM, Wolden SL, Terezakis SA, Bindra RS, Bakst RL. Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review. Adv Radiat Oncol. 2019;4:520-531. [PMID: 31360809 DOI: 10.1016/j.adro.2019.03.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
63 Kim B, Pena CD, Auguste DT. Targeted Lipid Nanoemulsions Encapsulating Epigenetic Drugs Exhibit Selective Cytotoxicity on CDH1 /FOXM1 + Triple Negative Breast Cancer Cells. Mol Pharmaceutics 2019;16:1813-26. [DOI: 10.1021/acs.molpharmaceut.8b01065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
64 Hoeman CM, Cordero FJ, Hu G, Misuraca K, Romero MM, Cardona HJ, Nazarian J, Hashizume R, McLendon R, Yu P, Procissi D, Gadd S, Becher OJ. ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis. Nat Commun 2019;10:1023. [PMID: 30833574 DOI: 10.1038/s41467-019-08823-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 48] [Article Influence: 13.0] [Reference Citation Analysis]
65 Welby JP, Kaptzan T, Wohl A, Peterson TE, Raghunathan A, Brown DA, Gupta SK, Zhang L, Daniels DJ. Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas. Front Oncol 2019;9:92. [PMID: 30873381 DOI: 10.3389/fonc.2019.00092] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
66 Himes BT, Zhang L, Daniels DJ. Treatment Strategies in Diffuse Midline Gliomas With the H3K27M Mutation: The Role of Convection-Enhanced Delivery in Overcoming Anatomic Challenges. Front Oncol 2019;9:31. [PMID: 30800634 DOI: 10.3389/fonc.2019.00031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
67 Tsoli M, Shen H, Mayoh C, Franshaw L, Ehteda A, Upton D, Carvalho D, Vinci M, Meel MH, van Vuurden D, Plessier A, Castel D, Drissi R, Farrell M, Cryan J, Crimmins D, Caird J, Pears J, Francis S, Ludlow LEA, Carai A, Mastronuzzi A, Liu B, Hansford J, Gottardo N, Hassall T, Kirby M, Fouladi M, Hawkins C, Monje M, Grill J, Jones C, Hulleman E, Ziegler DS. International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. J Neurooncol 2019;141:253-63. [PMID: 30446898 DOI: 10.1007/s11060-018-03038-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
68 Choi SA, Lee C, Kwak PA, Park CK, Wang KC, Phi JH, Lee JY, Chong S, Kim SK. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma. Cancer Lett 2019;442:161-9. [PMID: 30367915 DOI: 10.1016/j.canlet.2018.10.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
69 Dobson THW, Gopalakrishnan V. Preclinical Models of Pediatric Brain Tumors-Forging Ahead. Bioengineering (Basel) 2018;5:E81. [PMID: 30279402 DOI: 10.3390/bioengineering5040081] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
70 Singleton WGB, Bienemann AS, Woolley M, Johnson D, Lewis O, Wyatt MJ, Damment SJP, Boulter LJ, Killick-cole CL, Asby DJ, Gill SS. The distribution, clearance, and brainstem toxicity of panobinostat administered by convection-enhanced delivery. Journal of Neurosurgery: Pediatrics 2018;22:288-96. [DOI: 10.3171/2018.2.peds17663] [Cited by in Crossref: 32] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
71 Sultan D, Ye D, Heo GS, Zhang X, Luehmann H, Yue Y, Detering L, Komarov S, Taylor S, Tai YC, Rubin JB, Chen H, Liu Y. Focused Ultrasound Enabled Trans-Blood Brain Barrier Delivery of Gold Nanoclusters: Effect of Surface Charges and Quantification Using Positron Emission Tomography. Small 2018;14:e1703115. [PMID: 29966035 DOI: 10.1002/smll.201703115] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
72 Dias JNR, Aguiar SI, Pereira DM, André AS, Gano L, Correia JDG, Carrapiço B, Rütgen B, Malhó R, Peleteiro C, Goncalves J, Rodrigues CMP, Gil S, Tavares L, Aires-da-Silva F. The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma. Oncotarget 2018;9:28586-98. [PMID: 29983882 DOI: 10.18632/oncotarget.25580] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
73 Chen YH, Zeng WJ, Wen ZP, Cheng Q, Chen XP. Under explored epigenetic modulators: role in glioma chemotherapy. Eur J Pharmacol 2018;833:201-9. [PMID: 29864410 DOI: 10.1016/j.ejphar.2018.05.047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Hoeman C, Shen C, Becher OJ. CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma. Front Oncol 2018;8:191. [PMID: 29904623 DOI: 10.3389/fonc.2018.00191] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
75 Clymer J, Kieran MW. The Integration of Biology Into the Treatment of Diffuse Intrinsic Pontine Glioma: A Review of the North American Clinical Trial Perspective. Front Oncol 2018;8:169. [PMID: 29868485 DOI: 10.3389/fonc.2018.00169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
76 Meel MH, Metselaar DS, Waranecki P, Kaspers GJL, Hulleman E. An efficient method for the transduction of primary pediatric glioma neurospheres. MethodsX 2018;5:173-83. [PMID: 30622915 DOI: 10.1016/j.mex.2018.02.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
77 Lorenzo Pisarello M, Masyuk TV, Gradilone SA, Masyuk AI, Ding JF, Lee PY, LaRusso NF. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease. Am J Pathol 2018;188:981-94. [PMID: 29366679 DOI: 10.1016/j.ajpath.2017.12.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
78 Tsoli M, Liu J, Franshaw L, Shen H, Cheng C, Jung M, Joshi S, Ehteda A, Khan A, Montero-Carcabosso A, Dilda PJ, Hogg P, Ziegler DS. Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma. Oncotarget 2018;9:7541-56. [PMID: 29484131 DOI: 10.18632/oncotarget.24045] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
79 Pathania M, De Jay N, Maestro N, Harutyunyan AS, Nitarska J, Pahlavan P, Henderson S, Mikael LG, Richard-Londt A, Zhang Y, Costa JR, Hébert S, Khazaei S, Ibrahim NS, Herrero J, Riccio A, Albrecht S, Ketteler R, Brandner S, Kleinman CL, Jabado N, Salomoni P. H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. Cancer Cell 2017;32:684-700.e9. [PMID: 29107533 DOI: 10.1016/j.ccell.2017.09.014] [Cited by in Crossref: 104] [Cited by in F6Publishing: 109] [Article Influence: 20.8] [Reference Citation Analysis]
80 Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR, Bjerke L, Clarke M, Vinci M, Nandhabalan M, Temelso S, Popov S, Molinari V, Raman P, Waanders AJ, Han HJ, Gupta S, Marshall L, Zacharoulis S, Vaidya S, Mandeville HC, Bridges LR, Martin AJ, Al-Sarraj S, Chandler C, Ng HK, Li X, Mu K, Trabelsi S, Brahim DH, Kisljakov AN, Konovalov DM, Moore AS, Carcaboso AM, Sunol M, de Torres C, Cruz O, Mora J, Shats LI, Stavale JN, Bidinotto LT, Reis RM, Entz-Werle N, Farrell M, Cryan J, Crimmins D, Caird J, Pears J, Monje M, Debily MA, Castel D, Grill J, Hawkins C, Nikbakht H, Jabado N, Baker SJ, Pfister SM, Jones DTW, Fouladi M, von Bueren AO, Baudis M, Resnick A, Jones C. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell. 2017;32:520-537.e5. [PMID: 28966033 DOI: 10.1016/j.ccell.2017.08.017] [Cited by in Crossref: 332] [Cited by in F6Publishing: 388] [Article Influence: 66.4] [Reference Citation Analysis]
81 Long W, Yi Y, Chen S, Cao Q, Zhao W, Liu Q. Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma. Front Pharmacol 2017;8:495. [PMID: 28790919 DOI: 10.3389/fphar.2017.00495] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
82 Hashizume R. Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma. Neurol Med Chir (Tokyo) 2017;57:331-42. [PMID: 28592748 DOI: 10.2176/nmc.ra.2017-0018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
83 Nakata S, Nobusawa S, Yamazaki T, Osawa T, Horiguchi K, Hashiba Y, Yaoita H, Matsumura N, Ikota H, Hirato J, Yoshimoto Y, Yokoo H. Histone H3 K27M mutations in adult cerebellar high-grade gliomas. Brain Tumor Pathol 2017;34:113-9. [PMID: 28547652 DOI: 10.1007/s10014-017-0288-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
84 Killick-Cole CL, Singleton WGB, Bienemann AS, Asby DJ, Wyatt MJ, Boulter LJ, Barua NU, Gill SS. Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma. PLoS One 2017;12:e0176855. [PMID: 28542253 DOI: 10.1371/journal.pone.0176855] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
85 Nagaraja S, Vitanza NA, Woo PJ, Taylor KR, Liu F, Zhang L, Li M, Meng W, Ponnuswami A, Sun W, Ma J, Hulleman E, Swigut T, Wysocka J, Tang Y, Monje M. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. Cancer Cell 2017;31:635-652.e6. [PMID: 28434841 DOI: 10.1016/j.ccell.2017.03.011] [Cited by in Crossref: 150] [Cited by in F6Publishing: 165] [Article Influence: 30.0] [Reference Citation Analysis]
86 Lapin DH, Tsoli M, Ziegler DS. Genomic Insights into Diffuse Intrinsic Pontine Glioma. Front Oncol 2017;7:57. [PMID: 28401062 DOI: 10.3389/fonc.2017.00057] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]